Clinical trial
Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.
NCT01469156 is registered in ClinicalTrials.gov with Southeast Retina Center, Georgia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.
- Lead sponsor
- Southeast Retina Center, Georgia
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 30, 2011
- Completion date
- February 28, 2015
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.